¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ IGET Symposium 2020 / Á¦29Â÷ Á¤±âÇмú´ëȸ ¹× ÃÑȸ(1ÀÏÂ÷) (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) : 2020-07-24

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ IGET Symposium 2020 / Á¦29Â÷ Á¤±âÇмú´ëȸ ¹× ÃÑȸ(1ÀÏÂ÷) (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) : 2020-07-24
±³À°ÀÏÀÚ : 2020-07-24
±³À°Àå¼Ò : ¿ÀÇÁ¶óÀÎ & ¿Â¶óÀÎ µ¿½Ã °³ÃÖ ¿¬¼ö±³À° (¿ÀÇÁ¶óÀÎ: °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B)  
±³À°ÁÖÁ¦ : IGET Symposium 2020 / Á¦29Â÷ Á¤±âÇмú´ëȸ ¹× ÃÑȸ(1ÀÏÂ÷) (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà)
ÁÖÃÖ±â°ü : ´ëÇÑ¿µ»óÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ  
´ã´çÀÚ : ÁÖÇýÁ¤
¿¬¶ôó : 02-465-9070  
À̸ÞÀÏ : office@intervention.or.kr      
±³À°Á¾·ù : ¿µ»óÀÇÇаúÀÇ»çÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í ¿Â¶óÀÎ: »çÀüµî·Ï 10000¿ø / ¿ÀÇÁ¶óÀÎ-»çÀüµî·Ï: Á¤È¸¿ø.ÁØȸ¿ø.±âŸ 50000¿ø, Àü¹®ÀÇ 100000¿ø, °øº¸.Àü°øÀÇ 30000¿ø / ¿ÀÇÁ¶óÀÎ-ÇöÀåµî·Ï: Á¤È¸¿ø.ÁØȸ¿ø.±âŸ 70000¿ø, Àü¹®ÀÇ 120000¿ø, °øº¸.Àü°øÀÇ 50000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:00~09:05 IGET Symposium Opening Remark  () 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:05~09:20 My strategy of endovascular management for chronic dissection  ¹ÌÁ¤(¹ÌÁ¤) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:20~09:35 Long term durability of EVAR : Where do we stand?  °­Ã¤ÈÆ(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:35~09:50 Tips and tricks of hostile neck for EVAR  Çöµ¿È£(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:50~10:05 Endovascular management of iliac aneurysm  Àü¿ë¼±(ÀÎÇÏÀÇ´ë) 
Åä·Ð 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 10:05~10:20 Discussion  ±èâ¿ø(ºÎ»êÀÇ´ë) 
È޽Ġ07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 10:20~10:30 Coffee break  () 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 10:30~10:45 Recent update of Endovascular treatment of complex aortoiliac disease  À̸í¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 10:45~11:00 Latest results of stents in Femoropopliteal disease  Á¶¼ö¹ü(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:00~11:15 Endovascular treatment for femoropopliteal disease by DCB – Korea experience  ±èÁø¿ì(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:15~11:30 Latest information of Paclitaxel safety  ½Éµ¿Àç(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:30~11:45 What is the best options (POBA, DCB or DES) for BTK interventions?  ¹Ú»ó¿ì(°Ç±¹ÀÇ´ë) 
Åä·Ð 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:45~11:55 Discussion  ¿øÁ¦È¯(¾ÆÁÖÀÇ´ë) 
±âŸ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:55~12:00 IGET Symposium Closing Remark  () 
½Ä»ç 07-24  12:00~12:55 ½Ä»ç  () 
±âŸ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 12:55~13:00 Á¦29Â÷ Á¤±âÇмú´ëȸ Opening Remark  () 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:00~13:10 The impact of socioeconomic status on mortality in initial TACE candidates for HCC: A Korean national cohort study  ¾ç¿ìÁø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:10~13:20 Effectiveness of Adding Delayed-phase Cone-beam Computed Tomography for Hepatocellular Carcinomas Dectectability and Treatment  ±è¼­¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:20~13:30 Fluoroscopy-guided Double J urinary stent exchange via transurethral access in Male and Female patients  °ûÁ¤¿ø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:30~13:40 Lymphatic Embolization versus Sclerotherapy for Symptomatic Post-operative Pelvic Lymphocele (LESPOL): A Randomized Pilot Study  ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:40~13:50 Plug assisted retrograde trasvenous lymphatic embolization(PARLE) for thoracic duct embolization in chylothorax patient  ±ÇÈÆ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:50~14:00 Percutaneous lymphatic intervention for the treatment of postoperative lymphatic ascites related to pelvic surgery: analysis of factors affecting outcome  ÀÌ°æ¹Î(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:00~14:15 Procedure-related emergency  ¼Û¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:15~14:30 Periprocedural Management of Coagulation Status & Hemostasis Risk in Interventional Procedures  ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:30~14:45 Pain control / sedation  ±è¸¸µæ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:45~15:00 Surgical perspective  ³ë½Â¿¬(°æÈñÀÇ´ë) 
Åä·Ð 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:00~15:10 Discussion  Àü¿õ¹è ±èÇü¿í(ºÎ»êÀÇ´ë Àü³²ÀÇ´ë) 
È޽Ġ07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:10~15:30 Coffee break  () 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:30~16:00 Diagnostic reference level in IR  À̸í¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:00~16:10 Plug-assisted retrograde transvenous obliteration (PARTO) for duodenal varix via the right gonadal vein  ¾ç¿ìÁø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:10~16:20 Importance of pedal muscular branch in transcollateral pedal angioplasty  ±èÁ¤Àº(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:20~16:30 Amazing response of advanced HCC with intra-arterial chemotherapy  ±è¼ºÈ£(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:30~16:40 Transcatheter arterial embolization for chronic non-specific back pain (lumbar pain)  ÀÌ»óȯ(¾çÁöº´¿ø) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:40~16:50 lymphovenous microsurgery for intractable chylous ascites : role of intraoperative lymphangiography  Á¤À±¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:50~17:00 Percutaneous sclerotherapy for large thoracoabdominal lymphatic cyst  ½ÅÁöÈÆ(¿ï»êÀÇ´ë) 
Åä·Ð 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:00~17:10 Discussion  ÀÌ¿õÈñ °­¿õ·¡(¼øõÇâÀÇ´ë ´ë±¸°¡Å縯´ëÇб³º´¿ø) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:10~17:20 Cook Medical  ÀÌ¿ì¶÷(Cook Medical) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:20~17:30 ¢ß¼¼¸íMD  ÃÖÁø´ö(¢ß¼¼¸íMD) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:30~17:40 Boston Scientific  ÀÌÀºÁÖ(Boston Scientific) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:40~17:50 Philips  ±è½ÅÈ£(Philips) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2020³âµµ ´ëÇÑÀ̽ÄÇÐȸ Á¦16Â÷ Ãá°èÇмú´ëȸ (¿Â¶óÀÎ) : 2020-07-24
´ÙÀ½±Û ´ëÇѼºÇü¿Ü°úÇÐȸ Á¦10ȸ ±âÃÊÀç°Ç¼ºÇü Çмú´ëȸ (¿Â¶óÀÎ) : 2020-07-24
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20634 ´ëÀü 2024³â ´ëÀü±¤¿ª½ÃÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 13 2024-05-10
20633 ¼­¿ï ´ëÇѾȽŰæÀÇÇÐȸ Neurology of eye movements : 2024-05-18 0 23 2024-05-10
20632 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ KSMO Á¦ 22Â÷ Ãá°èÁ¤±â½ÉÆ÷Áö¾ö ¹× ÃÑȸ : 2024-05-17 0 7 2024-05-10
20631 ÀÎõ 2024³âµµ Á¦47Â÷ ´ëÇѺ¹ºÎ¿µ»óÀÇÇÐȸ Çмú´ëȸ(1ÀÏÂ÷) : 2024-05-17 0 5 2024-05-10
20630 ºÎ»ê Á¦28Â÷ ¾Æ½Ã¾Æ-¿À¼¼¾Æ´Ï¾Æ »êºÎÀΰú¿¬¸Í Çмú´ëȸ (AOFOG 2024) (1ÀÏÂ÷) : 2024-05-17 0 7 2024-05-10
20629 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ¿Â¶óÀÎ_¼­¿ï°æÀÎÁöȸ 276Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-17 0 3 2024-05-10
20628 ¼­¿ï 2024³â ´ëÇѹ财Àå¾Ö¿ä½Ç±ÝÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-17 0 9 2024-05-10
20627 ´ëÀü ´ëÇÑ»êºÎÀΰúÀÇ»çȸ ´ëÀüÁöȸ ¿¬¼ö±³À° : 2024-05-17 0 15 2024-05-10
20626 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-05-13 0 15 2024-05-10
20625 ´ëÀü Çѱ¹¿©ÀÚÀÇ»çȸ ´ëÀüÁöȸ 5¿ù Çмú½ÉÆ÷Áö¾ö(¾î±ú ÅëÁõ) : 2024-05-13 0 8 2024-05-10
20624 ¼­¿ï ´ëÇÑ·¹ÀÌÀúÇǺθð¹ßÇÐȸ Á¦46Â÷ Ãá°è Çмú´ëȸ : 2024-05-12 0 10 2024-05-10
20623 ¼­¿ï Á¦2ȸ ´ëÇѽŰæ°úÀÇ»çȸ Ãá°è ÀçÅÃÀÇ·á ½ÉÆ÷Áö¾ö : 2024-05-12 0 21 2024-05-10
20622 ´ë±¸ Á¦54ȸ ´ëÇѵΰæºÎ¿Ü°úÇÐȸ Áõ·ÊÇмú´ëȸ : 2024-05-11 0 12 2024-05-10
20621 °æºÏ 2024³â Á¦28ȸ ´ëÇÑÀü¸³¼±·¹ÀÌÀú¿¬±¸ÇÐȸ ÁýÁß½ÉÆ÷Áö¾ö : 2024-05-10 0 9 2024-05-10
20620 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼­¿ï¾Æ»êº´¿ø ´ç´¢º´ °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-30 0 177 2024-04-30
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷